http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2366617-T3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f2d571ab2bc191d9bc90c62c7dae922 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-85 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4738 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N63-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- |
filingDate | 2004-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2011-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c90a6c9eb17d84ef50678712029cc7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09dd649ff1d155ca3d6d8ef98dd9dcb3 |
publicationDate | 2011-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2366617-T3 |
titleOfInvention | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS. |
abstract | Method for producing a targeted administration vector comprising retroviral particles to inhibit tumor metastasis, said method comprising the following steps: A) transient transfection of a producing cell with: i) a first plasmid comprising a nucleic acid sequence encoding the 4070A envelope amphotropic protein modified to contain a collagen binding domain, in which the nucleic acid sequence is operably linked to a promoter, and in which the collagen binding domain comprises the amino acid sequence Gly-His-Val -Gly-Trp-Arg-Glu-Pro-Ser-Phe Met-Ala-Leu-Ser-Ala-Ala obtained from the D2 domain of von Willebrand factor; ii) a second plasmid, comprising: (a) a nucleic acid sequence operably linked to a promoter, and wherein the sequence encodes a gag-pol retroviral polypeptide, (b) a nucleic acid sequence operably linked to a promoter , and in which the sequence encodes a polypeptide that confers drug resistance to the producer cell, (c) an SV40 origin of replication; iii) a third plasmid, comprising: (a) a heterologous nucleic acid sequence operably linked to a promoter, and wherein the sequence encodes a diagnostic or therapeutic polypeptide, (b) 5'and 3 'long terminal repeat sequences '(LTRs), (c) a retroviral packaging sequence Ψ (d) a CMV promoter placed before the LTR 5' (e) a nucleic acid sequence operably linked to a promoter, and in which the sequence encodes a polypeptide that confers drug resistance to the producing cell, (f) an origin of SV40 replication, in which the producing cell is a human cell that expresses a large SV40 T antigen; B) culturing the producing cells according to A) under conditions that allow the production of targeted administration vectors and their release in the culture supernatants; (C) isolating and introducing the supernatants into a closed loop collector system comprising a flexboy® type bag and a collector system, in which the flexboy type bag is formed by a co-extruded three layer film consisting of a layer of contact with the fluid made of ethyl vinyl acetate, a gas barrier of Ethylene vinyl alcohol and an outer layer of ethyl vinyl acetate for the collection of viral particles; (D) collection and concentration of targeted delivery vectors, and (E) treatment of said targeted delivery vectors with a DNA degradation agent that does not cause a loss of vector potency. |
priorityDate | 2003-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 855.